. 2017 Jan 7;17:45. doi: 10.1186/s12879-016-2106-x

Table 3.

Observed sustained virological response rates in subgroups at 12 weeks (SVR12) after completing therapy with daclatasvir and sofosbuvir, with or without ribavirin

Subgroups		SVR12
		As-treated		Intent-to-treat
		%	Fraction	%	Fraction
Genotype^a	1	98	171/174	92	171/186
	3	94	33/35	85	33/39
	Other	94	15/16	88	15/17
Cirrhosis	None or compensated	100	93/93	99	93/94
Cirrhosis	Decompensated	95	126/132	85	126/148
Prior treatment	Naive	99	75/76	88	75/85
Prior treatment	Experienced	99	144/149	92	144/157
Ribavirin	Without	96	157/163	88	157/178
Ribavirin	With	100	62/62	97	62/64
Overall		97	219/225	90	219/242

^aGenotype for the 6 patients without a sustained virologic response 12 weeks after the end of treatment: 1a, 1b (n = 2), 3a (n = 2) and 5a